Xuejun Sun

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Topics

Epithelial Mesenchymal Transition

Top Venues

Cancer gene therapy

Cell death & disease

Oxidative medicine and cellular longevity

Journal of cellular and molecular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Mingchao Mu, Qin Zhang, Chenye Zhao, Xiaopeng Li, Zilu Chen, Xuejun Sun, Junhui Yu
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis. Cancer gene therapy (2023)
Junhui Yu, Kui Yang, Jianbao Zheng, Pengwei Zhao, Jie Xia, Xuejun Sun, Wei Zhao
Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell death & disease 14 (2) (2023)
Junhui Yu, Kui Yang, Jianbao Zheng, Pengwei Zhao, Jie Xia, Xuejun Sun, Wei Zhao
Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell death & disease 14 (2) (2023)
Mingchao Mu, Qin Zhang, Jing Li, Chenye Zhao, Xiaopeng Li, Zilu Chen, Xuejun Sun, Junhui Yu
USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A. Cell death and differentiation (2023)
Junhui Yu, Kui Yang, Jianbao Zheng, Pengwei Zhao, Jie Xia, Xuejun Sun, Wei Zhao
Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell death & disease 13 (4) (2022)
Junhui Yu, Kui Yang, Jianbao Zheng, Wei Zhao, Xuejun Sun
Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. Cancer gene therapy (2021)
Junhui Yu, Zhengshui Xu, Jing Guo, Kui Yang, Jianbao Zheng, Xuejun Sun
Tumor-associated macrophages (TAMs) depend on MMP1 for their cancer-promoting role. Cell death discovery 7 (1) (2021)
Junhui Yu, Shan Li, Zhengshui Xu, Jing Guo, Xiaopeng Li, Yunhua Wu, Jianbao Zheng, Xuejun Sun
CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression. British journal of cancer 124 (1) (2020)
Junhui Yu, Kui Yang, Jianbao Zheng, Wei Zhao, Xuejun Sun
Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. Cancer gene therapy 28 (6) (2020)
Shan Li, Zhengshui Xu, Jing Guo, Jianbao Zheng, Xuejun Sun, Junhui Yu
Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene. Journal of cellular and molecular medicine 24 (24) (2020)
Yunhua Wu, Guangbing Wei, Junhui Yu, Zilu Chen, Zhengshui Xu, Rui Shen, Ting Liang, Lu Zheng, Kang Wang, Xuejun Sun, Xuqi Li
Danhong Injection Alleviates Postoperative Intra-abdominal Adhesion in a Rat Model. Oxidative medicine and cellular longevity 2019 (2019)
Guangbing Wei, Yunhua Wu, Qi Gao, Cancan Zhou, Kai Wang, Cong Shen, Guanghui Wang, Kang Wang, Xuejun Sun, Xuqi Li
Effect of Emodin on Preventing Postoperative Intra-Abdominal Adhesion Formation. Oxidative medicine and cellular longevity 2017 (2017)